EGFR and non-small cell lung carcinoma: Such evidence leads to the development of tyrosine kinase inhibitors (TKIs) targeting the EGFR’s intracellular tyrosine kinase domain, which showed a significant effect on patients with advanced-stage NSCLC harboring EGFR mutation [4].